• 1.

    Row PG, et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 1975; 44:207239. https://doi.org/10.1093/oxfordjournals.qjmed.a067422

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Cahen R, et al. Aetiology of membranous glomerulonephritis: A prospective study of 82 adult patients. Nephrol Dial Transplant 1989; 4:172180. doi: 10.1093/oxfordjournals.ndt.a091852

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Thet Z, et al. Critical evaluation of cancer risks in glomerular disease. Transl Oncol [published online ahead of print February 24, 2022]. doi: 10.1016/j.tranon.2022.101376; https://www.sciencedirect.com/science/article/pii/S1936523322000389?via%3Dihub

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Leeaphorn N, et al. Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies. Am J Nephrol 2014; 40:2935. doi: 10.1159/000364782

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Bjørneklett R, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396403. doi: 10.1053/j.ajkd.2007.06.003

  • 6.

    Zhang D, et al. Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. Int J Biol Markers 2019; 34:406413. doi: 10.1177/1724600819882698

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Qu Z, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012; 27:19311937. doi: 10.1093/ndt/gfr534

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Heaf JG, et al. Quantification of cancer risk in glomerulonephritis. BMC Nephrol 2018; 19:27. doi: 10.1186/s12882-018-0828-2

  • 9.

    Pani A, et al. Glomerular diseases and cancer: Evaluation of underlying malignancy. J Nephrol 2016; 29:143152. doi: 10.1007/s40620-015-0234-9

  • 10.

    Nissan E, et al. The usefulness of [18F]FDG-PET/CT in detecting and managing cancers with unknown primary site depends on histological subtype. Sci Rep 2021; 11:17732. doi: 10.1038/s41598-021-96451-z

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Caza TN, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2021; 99:967976. doi: 10.1016/j.kint.2020.07.039

  • 12.

    Khan MB, et al. Complete resolution of paraneoplastic membranous nephropathy following curative therapy of triple-negative breast cancer. Cureus 2021; 13:e18125. doi: 10.7759/cureus.18125

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Adlington D, et al. Remission of membranous nephropathy after treatment of localised prostate cancer. Case Rep Nephrol Dial 2019; 9:7984. doi: 10.1159/000500948; https://core.ac.uk/download/pdf/237441013.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation

Malignancy-Related Membranous Nephropathy

Prabhat Chauhan Prabhat Chauhan, MBBS, MD, DM, is Assistant Professor with Indian Naval Hospital Ship (INHS), ASVINI, Mumbai, India. Raja Ramachandran, MBBS, MD, DM, is Associate Professor with the Department of Nephrology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.

Search for other papers by Prabhat Chauhan in
Current site
Google Scholar
PubMed
Close
and
Raja Ramachandran Prabhat Chauhan, MBBS, MD, DM, is Assistant Professor with Indian Naval Hospital Ship (INHS), ASVINI, Mumbai, India. Raja Ramachandran, MBBS, MD, DM, is Associate Professor with the Department of Nephrology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India.

Search for other papers by Raja Ramachandran in
Current site
Google Scholar
PubMed
Close
Restricted access
Save